Chadi G. Abdallah

Chadi G. Abdallah

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Chadi G. Abdallah

Department of Psychiatry, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
MLMark W. Logue
Mark W. Logue
SRSanne J.H. van Rooij
Sanne J.H. van Rooij
EDEmily L. Dennis
Emily L. Dennis
SDSarah L. Davis
Sarah L. Davis
JHJasmeet P. Hayes
Jasmeet P. Hayes
RMRajendra Morey
Rajendra Morey

17 March 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
JMJames W. Murrough
James W. Murrough
CAChadi G. Abdallah
Chadi G. Abdallah
SMSanjay J. Mathew
Sanjay J. Mathew

1 March 2019 in Neuron
Verified
Journal Article
Closed access
JKJohn H. Krystal
John H. Krystal
CAChadi G. Abdallah
Chadi G. Abdallah
GSGerard Sanacora
Gerard Sanacora
DCDennis S. Charney
Dennis S. Charney
RDRonald S. Duman
Ronald S. Duman

14 January 2015 in Annual Review of Medicine
Verified
Journal Article
Closed access
CAChadi G. Abdallah
Chadi G. Abdallah
GSGerard Sanacora
Gerard Sanacora
RDRonald S. Duman
Ronald S. Duman
JKJohn H. Krystal
John H. Krystal
Ketamine is the prototype for a new generation of glutamate-based antidepressants that rapidly alleviate depression within hours of treatment. Over the past decade, there has been replicated evidence demonstrating the rapid and potent antidepressant effects of ketamine in treatment-resistant depression. Moreover, preclinical and biomarker studies have begun to elucidate the mechanism underlying the rapid antidepressant effects of ketamine, offering a new window into the biology of depression and identifying a plethora of potential treatment targets. This article discusses the efficacy, safety, and tolerability of ketamine, summarizes the neurobiology of depression, reviews the mechanisms underlying the rapid antidepressant effects of ketamine, and discusses the prospects for next-generation rapid-acting antidepressants.

19 September 2017 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
TATeddy J. Akiki
Teddy J. Akiki
CAChristopher L. Averill
Christopher L. Averill
CAChadi G. Abdallah
Chadi G. Abdallah

8 September 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
CAChadi G Abdallah
Chadi G Abdallah
LALynnette A Averill
Lynnette A Averill
KCKatherine A Collins
Katherine A Collins
PGPaul Geha
Paul Geha
JSJaclyn Schwartz
Jaclyn Schwartz
James W. MurroughJames W. Murrough
James W. Murrough